Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Different Formulations of Inactivated Sars-Cov-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses Publisher Pubmed



Haghighi M1 ; Khorasani A1 ; Karimi P2 ; Keshavarz R3 ; Mahdavi M4, 5, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of FMD Vaccine Production, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
  2. 2. Department of Biochemistry, Faculty of Basic Sciences, Islamic Azad University, Tehran, Iran
  3. 3. PPD Tuberculin Department, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran
  4. 4. Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
  5. 5. Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Immunotherapy Group, The Institute of Pharmaceutical Science (TIPS), Tehran University of Medical Science, Tehran, Iran

Source: Viral Immunology Published:2022


Abstract

Several inactivated SARS-CoV-2 vaccines have been approved for human use, but are not highly potent. In this study, different formulations of the inactivated SARS-CoV-2 virus were developed in Alum, Montanide 51VG, and Montanide ISA720VG adjuvants, followed by assessment of immune responses. The SARS-CoV-2 virus was inactivated with formalin and formulated in the adjuvants. BALB/c mice were immunized subcutaneously with 4 μg of vaccines on days 0 and 14; (IL-4) and (IFN-g), cytotoxic T lymphocyte (CTL) activity, and specific immunoglobulin G (IgG) titer and IgG1, IgG2a, and IgG2a/IgG1 ratio, and anti-receptor-binding domain (RBD) IgG response were assessed 2 weeks after the final immunization. Immunization with SARS-CoV-2-Montanide ISA51VG showed a significant increase in the IFN-γcytokine versus SARS-CoV-2-Alum, SARS-CoV-2-Montanide ISA720VG, and control groups (p < 0.0033). Cytokine IL-4 response in SARS-CoV-2-Alum group showed a significant increase compared with SARS-CoV-2-Montanide ISA51VG, SARS-CoV-2-Montanide ISA720VG, and control groups (p < 0.0206). In addition, SARS-CoV-2-Montanide ISA51VG vaccine induced the highest IFN-γ/IL-4 cytokine ratio versus other groups (p < 0.0004). CTL activity in SARS-CoV-2-Montanide ISA51VG and SARS-CoV-2-Montanide ISA720VG groups showed a significant increase compared with SARS-CoV-2-Alum and control groups (p < 0.0075). Specific IgG titer in SARS-CoV-2-Montanide ISA51 VG and SARS-CoV-2-Montanide ISA720VG showed a significant increase compared with SARS-CoV-2-Alum and control groups (p < 0.0143). Results from specific IgG1and IgG2a in SARS-CoV-2-Alum, SARS-CoV-2-Montanide ISA51VG, and SARS-CoV-2-Montanide ISA720VG vaccine showed a significant increase compared with phosphate buffer saline (PBS) group (p < 0.0001), but SARS-CoV-2-Montanide ISA51VG and SARS-CoV-2-Montanide ISA 720VG groups showed the highest IgG2a/IgG1 ratio and a significant increase compared with SARS-CoV-2-Alum group (p < 0.0379). Moreover, inactivated SARS-CoV-2+Alum and SARS-CoV-2-Montanide ISA 720VG groups demonstrated a significant increase in anti-RBD IgG response versus the SARS-CoV-2-Montanide ISA51VG group. It seems that the type of vaccine formulation is a critical parameter, influencing the immunologic pattern and vaccine potency and human-compatible oil-based adjuvants were more potent than Alum adjuvant in the vaccine formulation. © Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.
Related Docs
View other Related Docs
1. Improvement of the Inactivated Sars-Cov-2 Vaccine Potency Through Formulation in Alum/Naloxone Adjuvant; Robust T Cell and Anti-Rbd Igg Responses, Iranian Journal of Basic Medical Sciences (2022)
2. Nanoadjuvants Produced by Advanced Nanochelating Technology in the Inactivated-Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Formulation: Preliminary Results on Cytokines and Igg Responses, Viral Immunology (2023)
3. Adjuvant Effects of Pseudomonas Aeruginosa Flagellin on the Immunological Patterns of the Hiv-1 Vaccine Candidate: Vaccine Formulations Versus Different Routes of Immunization, Viral Immunology (2022)
4. Formulation of Hbsag in Montanide Isa 51Vg Adjuvant: Immunogenicity Study and Monitoring Long-Lived Humoral Immune Responses, International Immunopharmacology (2021)
5. Formulation of a Recombinant Hiv-1 Polytope Candidate Vaccine With Naloxone/Alum Mixture: Induction of Multi-Cytokine Responses With a Higher Regulatory Mechanism, APMIS (2021)
6. Formulation of Hbs Antigen in Montanide Isa266 Shows Superiority to Commercial Hbsag Vaccine in the Induction of Humoral Immune Responses, Gastroenterology and Hepatology from Bed to Bench (2019)
7. Recent Developments in Sars-Cov-2 Vaccines: A Systematic Review of the Current Studies, Reviews in Medical Virology (2023)
8. Severe Acute Respiratory Syndrome-Coronavirus-2 Spike (S) Protein Based Vaccine Candidates: State of the Art and Future Prospects, Reviews in Medical Virology (2021)
Experts (# of related papers)
View all Related Experts
Mehdi Shafee Ardestani (3)
Nima Rezaei (2)
Other Related Docs
9. Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies, International Immunopharmacology (2021)
10. Therapeutic Application of Nanoparticles in Hepatitis Diseases: A Narrative Review (2011-2021), Current Pharmaceutical Biotechnology (2023)
11. The Chimera of S1 and N Proteins of Sars-Cov-2: Can It Be a Potential Vaccine Candidate for Covid-19?, Expert Review of Vaccines (2022)
12. Pseudomonas Aeruginosa Flagellin As an Adjuvant: Superiority of a Conjugated Form of Flagellin Versus a Mixture With a Human Immunodeficiency Virus Type 1 Vaccine Candidate in the Induction of Immune Responses, Journal of Medical Microbiology (2015)
13. Appraisal of Sars-Cov-2 Mutations and Their Impact on Vaccination Efficacy: An Overview, Journal of Diabetes and Metabolic Disorders (2022)
14. Glucomannan As a Dietary Supplement for Treatment of Breast Cancer in a Mouse Model, Vaccines (2022)
15. Improvement of Hepatitis B Vaccine to Induce Ifn-Γ Cytokine Response: A New Formulation, Microbial Pathogenesis (2021)
16. Recent Findings on the Coronavirus Disease 2019 (Covid-19); Immunopathogenesis and Immunotherapeutics, International Immunopharmacology (2020)
17. Risk Factors for Adverse Outcomes of Covid-19 Patients: Possible Basis for Diverse Responses to the Novel Coronavirus Sars-Cov-2, Life Sciences (2021)
18. Evaluation of Seroconversion Rate Following Sars Cov 2 Vaccination in Health Care Workers at Shahid Beheshti University of Medical Sciences, Avicenna Journal of Medical Biotechnology (2023)
19. Immune Responses to Hiv-1 Polytope Vaccine Candidate Formulated in Aqueous and Alcoholic Extracts of Propolis: Comparable Immune Responses to Alum and Freund Adjuvants, Microbial Pathogenesis (2020)
20. Current Advances and Challenges in Covid-19 Vaccine Development: From Conventional Vaccines to Next-Generation Vaccine Platforms, Molecular Biology Reports (2022)
21. Formulation of Recombinant H1n1 Hemagglutinin in Mf59 and Alum Adjuvants: A Comparison of the Vaccines Potency and Efficacy in Balb/C Mice, Viral Immunology (2023)